1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Amgen Debuts Oncology Biosimilars Bevacizumab And Trastuzumab In US

 
• By Dave Wallace

Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.

Amgen
Amgen has launched two US biosimilars • Source: Shutterstock

Amgen has launched its Kanjinti (trastuzumab-anns) biosimilar rival to Genentech's Herceptin and its Mvasi (bevacizumab-awwb) biosimilar version of Genentech's Avastin in the US.

The launch of Kanjinti, the first marketed US trastuzumab biosimilar – which was only approved a month ago and marked the fifth biosimilar trastuzumab to be approved in the US (Also see "FDA Approves Amgen And Allergan’s Kanjinti Trastuzumab Biosimilar" - Generics Bulletin, 14 June, 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

More from Business